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Abstract
Gene class, ontology, or pathway testing analysis has become increasingly popular in microarray data analysis. Such
approaches allow the integration of gene annotation databases, such as Gene Ontology and KEGG Pathway, to formally test
for subtle but coordinated changes at a system level. Higher power in gene class testing is gained by combining weak
signals from a number of individual genes in each pathway. We propose an alternative approach for gene-class testing
based on mixed models, a class of statistical models that:
a) provides the ability to model and borrow strength across genes that are both up and down in a pathway,
b) operates within a well-established statistical framework amenable to direct control of false positive or false discovery
rates,
c) exhibits improved power over widely used methods under normal location-based alternative hypotheses, and
d) handles complex experimental designs for which permutation resampling is difficult.
We compare the properties of this mixed models approach with nonparametric method GSEA and parametric method
PAGE using a simulation study, and illustrate its application with a diabetes data set and a dose-response data set.
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Introduction
To help increase power to detect microarray differential
expression and to better interpret findings, gene-class testing or
pathway analysis has become increasingly popular [1]. These
approaches allow the integration of gene annotation databases
such as Gene Ontology [2] and KEGG Pathway [3] to formally
test for subtle but coordinated changes at the system level.
Improved power of gene-class testing is gained by combining weak
signals from a number of individual genes in each pathway. In
addition, pathway analysis has been effectively used to examine
common features between data sets [4].
The most commonly used approach for pathway analysis, the
enrichment or overrepresentation analysis, uses Fisher’s exact test.
This method starts with a list of differentially expressed genes
based on an arbitrary cutoff of nominal p-values, and compares
the number of significant genes in the pathway to the rest of the
genes to determine if any gene-set is overrepresented in the
significant gene list. The Fisher’s exact test is implemented in a
number of software packages such as GOTM [5], WebGestalt [6],
GENMAPP [7], ChipInfo [8], ONTO-TOOLS [9], GOstat [10],
DAVID [11], and JMP Genomics (http://www.jmp.com/
genomics). Although straightforward to implement and interpret,
this method loses information by using only the significant genes
resulted from arbitrarily dichotomizing p-values at some threshold.
More recent approaches such as Gene Set Enrichment Analysis
(GSEA) [12,13] and its extensions use continuous distributions of
evidence for differential expression and are based on a modified
version of the Kolmogorov-Smirnov test that compares the
distribution of test statistics in a pathway to the test statistics for
the rest of the genes. However, as explained in [14], the specific
alternative hypothesis for coordinated association between genes
in a gene-set with phenotype is likely to be a location change from
background distribution. The Kolmogorov-Smirnov test used by
GSEA, which detects any changes in the distribution, is often not
optimally powerful for detecting specific location changes. In
addition, false positives may result when genes in a gene-set have
different variances compared with genes outside the pathway.
Methods that test for location changes include PAGE [15] and
Functional Class Scoring [16]. PAGE uses normal distribution to
approximate test statistics based on differences in means for gene-
set genes and other genes; Functional Class Scoring method
computes mean (-log(p-value)) from p-values for all genes in a
gene-set, and compares this raw score to an empirically derived
distribution of raw scores for randomly selected gene-sets of the
same size using a statistical resampling approach.
PLoS Genetics | www.plosgenetics.org 1 July 2008 | Volume 4 | Issue 7 | e1000115Other examples of permutation- and bootstrap-based methods
include SAFE [17], iGA [18] and GSA [19]. However,
resampling-based methods rely on exchangeability that may be
hard to achieve in complex experimental designs. For example, in
designs with multiple random effects and/or time-series covari-
ance structures, great care must be taken to achieve an appropriate
resampling-based null distribution. In this paper, we propose an
alternative, parametric approach for gene-class testing based on
mixed linear models [20], which can readily accommodate
complex designs under standard parametric assumptions.
Some parametric methods and their comparisons with the
proposed method are in order. Wolfinger et al. [21] and Chu et al.
[22] considered using mixed models for detecting differentially
expressed genes for cDNA and Affymetrix microarrays. Ng et al.
[23] proposed random effects models to cluster gene expression
profiles, but their gene-sets are derived by statistical learning, not
based on biological knowledge. Other parametric models include
the random effect model of Goeman et al. [24] and the ANCOVA
model of Mansmann [25] for testing whether a particular gene-set
contains any gene associated with outcome. There is an important
distinction between these models and our proposed model. Tian et
al. [14] formulated two statistical hypothesis for testing coordi-
nated association between a group of genes with a phenotype of
interest: hypothesis Q1 - The genes in a gene-set show the same
pattern of associations with the phenotype compared with the rest
of the genes; and hypothesis Q2 - The gene-set does not contain
any genes whose expression levels are associated with the
phenotype of interest. Goeman et al. [24] and Mansmann et al.
[25] both test Q2 whereas our proposed model tests Q1. The most
similar parametric method with our proposed model that tests Q1
is PAGE [15] mentioned above; test statistics for both PAGE and
the proposed method are based on differences in means for gene-
set genes and other genes. Our method can be viewed as an
extension of PAGE with the ability to account for design of
experiment (e.g. covariate adjustment) and modeling dependency
between genes with a more general covariance structure.
In Materials and Methods, we describe the proposed mixed
model, including assumptions and interpretations. This model
incorporates both fixed effects (e.g. type of tissues, cases vs.
controls) and random effects which are assumed to be sampled
from a normal distribution and naturally fall into a hierarchical
empirical Bayes framework. The inclusion of random effects both
facilitates inferences to be made to the underlying population
represented by the observed samples and is a simple mechanism
for modeling a covariance structure within groups of correlated
observations. Another advantage is that mixed models provide a
powerful, unified and flexible framework that allows one to
conduct hypothesis testing for gene-sets and accounting for other
design factors at the same time. With mixed models, between-
arrays normalization, adjusting for covariates and gene-set testing
are achieved in a single step; in contrast, other gene-class testing
methods usually require separate data processing steps for
normalization, assessing statistical significance of individual genes
using a test statistics such as the t-score, and comparison of the test
statistics for genes in the pathway with non-pathway genes. In the
Results section, we first confirm the increased power over the
nonparametric method GSEA and parametric method PAGE
using simulations and then illustrate the method using two
microarray datasets, a human diabetic muscle dataset [12] and a
dose-response study [26]. In the Discussion section, we provide
some concluding comments.
Materials and Methods
Given two groups of samples and an a priori defined set of genes
from a particular pathway, we are interested in testing whether the
differential expression between the groups are significantly
different for genes in the pathway compared with the rest of the
genes. For sake of concreteness we assume without loss of
generality the two groups of samples are from patients with a
disease phenotype (cases) and otherwise (controls).
Data Preprocessing
We assume reliable numerical values are obtained from gene
expression intensities and are on the log2 scale. In single colored
arrays, the expression values for each gene are derived from each
spot on the array; in two-colored arrays, the expression values for
each gene can be the original intensities or the ratios of expression
values for experimental sample compared to reference sample.
When multiple probe sets for a gene are present, they can be
mapped to some standard gene IDs such as the Ensembl Gene IDs
(http://www.ensembl.org) and the median is used for further
analysis. This is often done for computational efficiencies of larger
arrays. In the following discussion, we assume there is one value
for each gene, at the end of the Discussion section, we discuss
extensions of basic mixed model to accommodate multiple gene
expression values per gene.
Next, to homogenize variances for all the genes included in
mixed model and to make their means comparable, we
standardize values for each gene with control group mean and
standard deviations. Specifically, the mean and standard deviation
of each gene from control patients are calculated, and all the gene
values are standardized by subtracting the control group mean and
dividing by the control group standard deviation. The standard-
ized gene expression values then represent the number of standard
deviations away from the ‘‘normal’’ gene expression values. In a
time course experiment, expression values at baseline can be used
similarly as control group data to standardize all measurements in
the time course.
Linear Mixed Model
Linear mixed models is a class of statistical models that handles
data where observations are not independent, such as gene
expression values from the same array. They include both fixed
effects and random effects, and thus are called mixed effect
models. The fixed effects model the systematic effects or the mean
structure of data, and the random effects account for complex
covariance structure of observations, such as those between genes.
In addition, they also allow inferences to be made to the entire
population of samples from which the observed samples arise.
Author Summary
In microarray data analysis, when statistical testing is
applied to each gene individually, one is often left with too
many significant genes that are difficult to interpret or too
few genes after a multiple comparison adjustment. Gene-
class, or pathway-level testing, integrates gene annotation
data such as Gene Ontology and tests for coordinated
changes at the system level. These approaches can both
increase power for detecting differential expression and
allow for better understanding of the underlying biological
processes associated with variations in outcome. We
propose an alternative pathway analysis method based
on mixed models, and show this method provides useful
inferences beyond those available in currently popular
methods, with improved power and the ability to handle
complex experimental designs.
Statistical Analysis of Biological Pathways
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per gene from each array, we propose the following basic linear
mixed models for comparing differential expression pattern in the
pathway (or gene-set) m and the rest of genes:
Model 1: ygjklm~mjkzArraylzPathwaymg ðÞ zegjklm
Here, y represents log transformed gene expression values, j=1if
gene g is from the pathway m and j=0 otherwise; k=1 for case
values and k=0 for control values. The parameters mjk model
systematic effects or fixed effects affecting gene expression values,
and correspond to a classical cell-means model [27]. The fixed
effects portion of Model 1 is equivalent to a model with intercept,
indicator variable Group (case or control), indicator variable
Pathway m (yes or no), and Group6Pathway m interaction effects.
Although Model 1 does not include gene-specific fixed effects, we
account these through standardization of gene values (Data
Preprocessing in Materials and Methods) which makes expression
values from different genes comparable and homogenizes their
variances.
Whilemjk are fixed unknown parametersto be estimated from data,
the terms Arrayl and Pathwaym(g) for l-th array and m-th pathway are
random variables, we use the subscript (g) to emphasize values for
Pathway random effects vary according to genes. We discuss in detail
the construction of these random effects and the specific covariance
structure accounted by them in the Materials and Methods section.
Finally, e represents variations due to measurement error and we
assume egjklm,N(0, s
2). Parameters from the mixed model are
estimated using the method of restricted maximum likelihood
(REML) along with appropriate standard errors.
The hypothesis we are testing is whether the amount of
differential expression between cases and controls for gene-set
genes are significantly different from the other genes. This is
essentially the interaction effect between gene-set and group. In
terms of Model 1, we want to test H0:(m112m10)2(m012m00)=0.
Here, m112m10 represents differential expression for genes in the
pathway and m012m00 represents differential expression for the rest
of the genes.
In feedback or reverse regulation, in response to an input signal,
genes in a gene-set may shift in both directions, that is, a fraction
of gene-set genes are up-regulated and another fraction of gene-set
genes are down-regulated, then testing changes in the entire gene-
set will not be effective as the changes in different directions will
cancel each other out. Instead, we propose modeling reverse
regulation with
Model 2: ygijklm~mijkzArraylzPathwaymg ðÞ zegijklm
where i indicates direction of changes for gene g, i=1 for up-
regulated genes and i=0 for down-regulated genes. With
this model, we estimate ^ D~ ^ m111{^ m110
  
{ ^ m101{^ m100
     
z
{ ^ m011{^ m010
  
{ ^ m001{^ m000
        
~0 where ^ m111{^ m110
  
{
^ m101{^ m100
  
estimates amount of up-regulation and ^ m011{^ m010
  
{ ^ m001{^ m000
  
estimates amount of down-regulation.
Because the direction of change i for each gene is estimated
from data, the hypothesis we are testing in this case is equivalent to
H0:{[(m112m10)2(m012m00)|i=1]2[(m112m10)2(m012m00)|i=0]}=0.
Therefore, ^ D~ ^ m11{^ m10
  
{ ^ m01{^ m00
  
i~1 j
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^ m01{^ m00
  
i~0 j   is the difference of two conditional random
variables, its distribution is a skewed unimodal distribution and can
not be approximated well using normal distribution. We propose a
Box-Cox transformation [28] of the test statistics to account for this.
Specifically, to test forsignificanceofn (e.g. 500) gene-sets, we follow
these steps:
1. Generate gene expression values for n ‘‘null gene-sets’’, see
details below.
2. For each null gene-set, fit Model 2 to data and calculate t-
statistics TD corresponding to estimate D ˆ.
3. Consider t-statistics for all null gene-sets, let TD+=TD2
min(TD) where min(TD)=minimum over all t-statistics, so that
TD+$0. The Box-Cox transformation of Tz
D is defined by
T
l ðÞ
Dz~
Tl
Dz{1
l l=0
ln TDz l~0
(
where l maximizes the function
l l ðÞ ~{
n
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1
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n
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Dzand T
l ðÞ
Dz,j~transformed test statistic
forjth gene-set. The Box-Cox transformation ensures the
transformed variable T
^ l
  
Dz can be well approximated by a
normal distribution.
4. With estimated ^ l, apply the Box-Cox transformation to t-
statistics corresponding to those gene-sets to be tested to obtain
T
^ l
  
Dz,TEST. Here, TD+,TEST is calculated by subtracting mini-
mumfrom t-statisticsofall gene-sets to be tested. Thep-value for
a particular gene-set j witht-statistics t canthen be approximated
by Pr T
^ l
  
Dz,TEST,jwt
  
~1{W
t{T T
^ l ðÞ
Dz;TEST ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var T
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Dz;TEST
   r
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> > <
> > :
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> > =
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where W(?)
is c.d.f. of standard normal distribution.
We use the Monte Carlo simulation approach [29] to simulate
gene expression values with the same covariance structure as those
in real microarray data. First, we fit Model 2 to real microarray
data and estimate covariance parameters corresponding to
variance components for random effects and residual errors e.
Next, we simulate gene values with random effects and errors
generated according to the estimated covariance parameters.
Because the dependency between genes are captured approxi-
mately by random effects and covariance parameters in mixed
models (Materials and Methods), the simulated gene expression
values will have essentially the same covariance structure as gene
values in real microarray data. Also, since no fixed effects were
added, the simulated data do not depend on outcome and
therefore correspond to null gene-sets values.
Once we obtain nominal p-values from steps described above,
we next calculate adjusted p-values to control for False Discovery
Rate (FDR). An adjusted p-value of 0.05 for a gene set indicates
that among all significant gene sets selected at this threshold, 5 out
100 of them are expected to be false leads.
Random Effects and Covariance Structure Modeled by
Mixed Model
In Models 1 and 2, we assume normal distributions for the
random effects: Array1,Array2,...,ArrayNarray*N 0,s2
array
  
and
Pathway1 g ðÞ ,...,PathwayNpathway g ðÞ *N 0,s2
pathway
  
. Here, the
Array random effects model effects due to sample variations and
Pathway random effects represent variations associated with
different biological processes defined by pathways. The random
effects have the advantage of requiring only a single parameter
(e.g. s2
array), the variance component, to be estimated. In the
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For real microarray dataset, one can also construct a separate
pathway ‘‘other’’ to include all genes not belonging to any gene-
sets to be tested.
Another important advantage of random effects is that they help
capture the heterogeneous covariations across genes. In particular,
the Array random effects account for covariance among all
observations from the same array and Pathway random effects
account for covariance among genes from the same pathway. Note
that the random Pathway effects vary according to genes, to model
different amount of dependencies between pairs of genes. We
discuss the specific covariance structure accounted by these
random effects and their constructions in details next.
The Array random effects are constructed as indicator variables for
each array, that is, Arrayl=I{array l}. To construct the Pathway ran-
dom effects, first, calculate t-statistics for each gene based on observed
data. Let X1,...,XNcontrols be gene expression values from control
samples, and Y1,...,YNcases be gene expression values from case
samples. Compute Tg~ Yg{Xg
  
, ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P nc
i~1
Xgi{Xg
   2.
nc{1 ðÞ
s
where X ¯g and Y ¯g are average gene values for control samples and case
samples respectively. Next, we construct Pathwaym(g)=Tg6I{pathway
m}, where I(pathway m) is indicator variable for a gene belonging to
pathway m. Therefore, for genes within pathway m, Pathwaym(g) varies
depending on Tg and it is 0 for genes outside pathway m.
Using matrix algebra, it can be shown that Array and Pathway
random effects induce a covariance structure in the marginal
model that accommodates different amount of dependencies
between genes (see for example, [29], page 737). More specifically,
let yglm be gene expression value for gene g from pathway m on
array l, then var yglm
  
~s2
arrayzs2
pathwayzs2 where s
2 is residual
variance associated with measurement errors and
Cov yglm,yg0l0m0
  
~
tgtg0s2
pathwayzs2
array if l~l0, m0~mA ðÞ
tgtg0s2
pathway if l=l0, m0~mB ðÞ
s2
array if l~l0, m0=mC ðÞ
0i f l=l0, m0=mD ðÞ
8
> > > > <
> > > > :
Here, tg denotes value of statistic T for gene g. In (B), for genes
from the same pathway, the correlations between genes depend on
directions and magnitudes of their differential expression changes.
So two genes are highly positively correlated if there are large
differential expression changes for both genes and their changes
are in the same direction. In (C), assuming most of covariations
between genes come from those genes within the same pathway
and genes from different pathways but on the same array are only
weakly correlated, we model a common covariance between these
genes. In practice, we found assuming heterogenous covariances
tgtg0s2
array tend to be too strong for genes from different pathways
and tests for gene-sets based on it lose too much power.
Comparing (A) and (B), (C), genes from the same arrays and
pathways are more correlated than those from different arrays or
from different pathways. In (D), we assume genes from different
arrays and different pathways are independent given the arrays are
from independent patients.
Results
Simulation Study
We performed a simulation study to assess the sensitivity and
specificity of a mixed model approach compared with GSEA and
PAGE which also test hypothesis Q1 in Tian et al. [14], that is, the
association of gene-set genes with outcome is similar with the
association for the rest of the genes. For each scenario in Table 1,
two sets of 50 microarray samples were simulated for treatment
and control groups. Each sample consisted of 1500 values
generated from the standard normal distribution as an approxi-
mation to log transformed gene expression values. These values
were assigned to 50 gene-sets, each with 30 genes. Treatment
effects were added to gene-set 1 according to the parameters p, up,
m where
p=Proportion of genes with treatment effect added to
case group,
up=Among treated genes, the proportion of genes for
which positive treatment effect m were added,
12up=Among treated genes, the proportion of genes
for which negative treatment effects 2m were added.
Therefore, among all the genes in the gene-set, there were
306p6up up-regulated genes and 306p6(12up) down-regulated
genes. For example, for Scenario 1 in Table 1, there were 9
(=30 60.3) genes in gene-set 1 with treatment effect added, among
them 5 (<3060.360.5) gene values were increased with 0.2 units
and the remaining 4 genes were decreased with 20.2 units. In
scenes 4–6 and 7–9, the total proportions of genes with treatment
effects were changed to 0.5 and 0.8 respectively. In scenes 10–18,
among treated genes, 80% of genes were moved up and 20%
genes were moved down. These parameters were chosen to
represent different degrees of feedback and reverse regulation. For
each scenario, only the first gene-set was associated with
treatment-control groups and the other gene-sets were null gene-
sets by design of experiment.
The javaGSEA implementation was used for GSEA analysis
and the algorithm described on page 10 of [15] was used for
PAGE. SAS PROC MIXED [29] was used for mixed model
analysis. For datasets with up_p=0.5, GSEA algorithm was
implemented with gene list sorting mode ‘‘abs’’, so genes were
sorted based on absolute values; the mixed model was imple-
mented with Model 2. For each scenario with up_p=0.5, ^ l was
estimated by applying Box-Cox transformation (Linear Mixed
Model in Materials and Methods) to t-statistics of the 49 null gene-
sets. The results showed the estimated ^ l was 0.7 for all scenarios
for the transformed t-statistics to achieve approximate normality.
To compare the performances of Mixed Model 1 with GSEA
and PAGE, we generated 20 datasets for each set of parameters p,
up, m and computed the Area Under the receiver operating
characteristic Curve (AUC) for each method. The receiver
operating characteristic (ROC) curves show trade-off between
sensitivity and 1-specificity as the significance cutoff is varied. The
AUC assesses the overall discriminative ability of the methods at
determining whether a given gene-set is associated with outcome
over all possible cutoffs. In addition, we calculated the test sizes of
each method (the proportions of p-values less than 0.05 for null
gene-sets). Because under the null hypothesis we expect the p-
values to follow a uniform distribution, a method with test size
equal to or less than the significance cutoff (e.g. 0.05) is desirable.
In terms of AUC, when most genes are shifted in one direction
(up_p=0.8), the mixed model and PAGE performed similarly,
and they both outperformed GSEA consistently across scenarios
10–18 (Table 1, Figure 1). These results show that improved
power can be gained over GSEA, which tests for any differences in
distributions, by using approaches such as the mixed model or
PAGE that test for location changes. When genes are shifted in
both directions equally (up_p=0.5), the mixed model performed
Statistical Analysis of Biological Pathways
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mixed model vs. PAGE shows that combining signals for up-
regulation and down-regulation by Mixed Model 2 is more
effective in this setting because signals from genes shifted in
different directions may be cancelled out. We note also that all
methods maintained proper test sizes for all scenarios.
Reanalysis of Diabetes Study Data
Mootha et al. [12] compared gene expression of skeletal muscle
biopsy samples from human diabetes patients and patients with
normal glucose tolerance. There were 17 control patients (group
NGT) and 18 diabetic patients (group DM2) in this study and 149
curated gene-sets were tested for enrichment using GSEA. They
found that genes involved in oxidative phosphorylation were
coordinately down regulated in human diabetes. To compare the
results of the mixed model approach with GSEA and to confirm
that mixed models can also detect subtle but coordinated changes
in gene expression within gene-sets, we reanalyzed this data set.
Table 2 tabulates analysis results for gene-sets selected by mixed
models and the GSEA method. The results for GSEA were
obtained from http://www-genome.wi.mit.edu/mpg/oxphos/.
For the mixed model method, the nominal p-value were estimated
by fitting Model 1 and testing the interaction term Type6Path-
way. Because the Pathway random effects were also included in
Model 1, they induce a more general covariance structure between
genes, so mixed model analysis accounts for heterogeneous
variances of different pathways and gene-gene correlations. False
discovery rate (FDR) adjusted p-values were also calculated, an
adjusted p-value of 0.05 for a pathway indicates that among all
significant pathways selected at this threshold, 5 out 100 of them
are expected to be false leads.
The results show that both the mixed model and GSEA selected
the pathway ‘‘OXPHOS_HG_U133A_probes’’ as the most
significantly changed pathway and ranked the pathways ‘‘human_
Table 1. Area Under ROC Curve (AUC) for the comparison of
Mixed Model, PAGE and GSEA methods using simulated data.
Scene tot_p up_p mu Mixed Model GSEA PAGE
1 0.3 0.5 0.2 0.6158 0.5468 0.5453
2 0.3 0.5 0.4 0.9346 0.6762 0.5852
3 0.3 0.5 0.6 0.9986 0.7349 0.6230
4 0.5 0.5 0.2 0.7735 0.7417 0.5452
5 0.5 0.5 0.4 0.9868 0.7321 0.5851
6 0.5 0.5 0.6 1.0000 0.7373 0.6225
7 0.8 0.5 0.2 0.9106 0.7394 0.5063
8 0.8 0.5 0.4 1.0000 0.7373 0.5064
9 0.8 0.5 0.6 1.0000 0.7373 0.5062
10 0.3 0.8 0.2 0.7074 0.6395 0.7002
11 0.3 0.8 0.4 0.8814 0.8484 0.8755
12 0.3 0.8 0.6 0.9718 0.9710 0.9683
13 0.5 0.8 0.2 0.8472 0.7173 0.8456
14 0.5 0.8 0.4 0.9872 0.9750 0.9888
15 0.5 0.8 0.6 0.9999 0.9957 1.0000
16 0.8 0.8 0.2 0.9551 0.8969 0.9572
17 0.8 0.8 0.4 1.0000 0.9956 1.0000
18 0.8 0.8 0.6 1.0000 0.9964 1.0000
tot_p=proportion of genes with treatment effect added to treatment group.
up_p=among treated genes, the proportion of genes for which positive
treatment effect mu was added.
1-up=among treated genes, the proportion of genes for which negative
treatment effect - mu was added.
doi:10.1371/journal.pgen.1000115.t001
Figure 1. Area under ROC Curves (AUC) for the comparison of Mixed Model, PAGE and GSEA methods using simulated data. For
each scene, there were 20 simulated datasets, each with 1500 genes assigned to 50 gene-sets, among them only the first gene-set (gene-set 1)
include genes associated with outcome by design. The test results from each method were compared with true classification of the gene-sets. The
AUC measures the ability of a test to correctly classify whether a gene-set is associated with outcome. In scenes 1–9, when genes were shifted in both
directions equally (up_p=0.5), mixed model outperformed both GSEA and PAGE. In scenes 10–18, when most of genes were shifted in one direction
(up_p=0.8), mixed model and PAGE performed similar, and they both outperformed GSEA, especially when the magnitude of differential expression
in gene-set 1 is small (scenes 10, 13, 16).
doi:10.1371/journal.pgen.1000115.g001
Statistical Analysis of Biological Pathways
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probes’’ high on their significant pathways list. While mixed model
selected 9 gene-sets at 5% FDR level, all FDR adjusted p-values for
GSEA method were greater than 0.2 (the minimum was 0.447). As
diabetes is primarily a chronic disorder of carbohydrate metabo-
lism, additional pathways identified by the mixed model, such as the
‘‘Glycolysis/Gluconeogenesis’’ and ‘‘Starch and sucrose metabo-
lism’’ make biological sense. Chronic diabetes has also been
associated with changes in ‘‘Tyrosine metabolism’’ [30], another
pathway identified by the mixed model.
A Dose Response Study
We next applied the mixed model method to a dose-response
microarray experiment. West et al. [26] conducted experiments to
study the effect of HNE (4-hydroxy-2-nonenal) on RKO human
colorectal carcinoma cells. It is postulated that HNE induces
cellular dysfunction in a variety of disorders such as inflammation,
cancer, neurodegenerative, cardiovascular disease [31,32]. In this
study, Affymetrix U133 Plus 2.0 chips were used with RKO cells
to explore transcriptional changes induced following treatment for
6 or 24 hours with 5,20, or 60 mM HNE. Figure S1 shows the
dose response relationships averaged over all genes for each gene
set for each treatment duration.
Our main objective was to identify gene sets with significant
monotone changes over doses and to assess whether the changes
were similar for the two treatment durations. With permutation
based methods such as GSEA, one needs to decide a priori whether
to test for trends of gene expression over different doses of HNE
for each treatment duration separately or to test for trends by
pooling data from both treatment durations. In contrast, the
mixed model framework provides a more efficient way to
incorporate information from both treatment durations, and
standard methods apply for testing polynomial trends of gene
expressions over different doses of HNE and for testing trend by
treatment duration interaction.
We next describe the analysis workflow. First, probe sets were
mapped to Ensembl Gene IDs and median expression levels for
multiple probe sets corresponding to the same gene were
calculated. After this step, we were left with 17278 genes and
they were tested for enrichment against gene sets generated based
on the biological process categories in Gene Ontology. Genes in
the human genome were mapped to GO categories according to
Ensembl annotation (http://www.ensembl.org). We focused on
GO categories with 10 to 200 genes by removing all the other
categories. Note that this is the size of a gene set when all of the
genes in the genome are considered. For genes on a specific array,
the gene counts for a gene set will be slightly smaller. In order to
reduce the redundancy in GO, we further removed all child-
categories if corresponding parent-category was within the size
limitation. After the above processes, 444 remaining gene sets were
used for the enrichment analysis.
Next, we calculated means and standard deviations for each
gene at dose 0 for each treatment duration separately and then
used these values to standardize all gene expression values. That is,
the values for each gene were standardized by subtracting the dose
0 means and dividing by dose 0 standard deviations. The
standardized gene expression values then represented the number
of standard deviation away from the ‘‘normal’’ gene expression at
dose 0.
Finally, we applied the mixed model with fixed effects Dose,
Treatment Duration, Dose6Treatment Duration to the gene
expression values. Because the data were collected at different
times, the variable Batch was also added to adjust for the effects of
different batches. In addition, a random Array effect was included
in the model to account for correlations of genes from the same
array and to facilitate inference to an entire population of arrays,
not only to those considered in this study. Contrasts of parameters
from this model based orthogonal polynomial coefficients were
then used to test for linear trend of expression values over doses
and Duration6Linear trend effect. The orthogonal polynomial
coefficients are linear transformations of the natural polynomial
scores and they alleviate collinearity problems of natural
polynomial scores. Adjusted p-values were then computed using
the R multtest package [33] to control for False Discovery Rate
(FDR) using the method of Benjamini and Hochberg [34].
Because we were mainly interested in gene sets directly
responding to changes in HNE, our analysis focused on gene sets
with significant linear trends of expression values corresponding to
monotone changes over doses. At the adjusted p-value level of
0.01, we identified 5 and 1 responsive gene sets for 6 h and 24 h
treatment, respectively (Figure 2). However, after testing for a
Duration6Linear Trend interaction, and refitting gene sets for
which the interaction was nonsignificant, we identified 40
responsive gene sets at the adjusted p-value level of 0.01
Table 2. Comparison of Mixed Model and GSEA Results for the Analysis of Diabetes Dataset from Mootha et al. (2003).
Pathway Nominal p-values FDR Adj. p-value
Size GSEA Mixed Model Mixed Model
OXPHOS_HG_U133A_probes 114 0.003 1.40E-12 2.11E-10
c18_U133_probes 248 0.932 4.43E-07 3.34E-05
human_mitoDB_6_2002_HG_U133A_probes 594 0.091 6.97E-06 3.51E-04
mitochondr_HG_U133A_probes 615 0.087 2.03E-05 7.68E-04
c25_U133_probes 64 0.246 9.07E-04 0.027
MAP00350_Tyrosine_metabolism 47 0.965 0.00110 0.028
c19_U133_probes 203 0.778 0.00253 0.048
MAP00010_Glycolysis_Gluconeogenesis 91 0.759 0.00255 0.048
MAP00500_Starch_and_sucrose_metabolism 30 1 0.00294 0.049
Size refers to the number of genes in the gene-set. Both mixed model and GSEA selected the pathway ‘‘OXPHOS_HG_U133A_probes’’ as the most significantly changed
pathway and ranked the pathways ‘‘human_mitoDB_6_2002_HG_U133A_pro’’, ‘‘mitochondr_HG_U133A_probes’’ high on their significant pathways list. Mixed model
selected 6 additional gene-sets at 5% FDR level.
doi:10.1371/journal.pgen.1000115.t002
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identified in the individual test. These 36 gene sets represented
some important biological processes that are known to be
responsive to HNE treatment, such as ‘‘mismatch repair’’,
‘‘double-strand break repair’’, and ‘‘response to inorganic
substance’’ (Table S1). These results demonstrated that pooling
data with similar trends from both treatment durations is helpful
for improving statistical power and identifying biologically
meaningful gene sets.
On the other hand, the interaction tests were also used to select
gene sets showing different response trends for the 6 h and 24 h
treatments. Among the 12 gene sets with significant interactions
(p-value,0.01), 8 of them were responsive for 6 h treatment
(adjusted p-value,0.05) but not for 24 h treatment (adjusted p-
value.0.95, see Figure 3). These gene sets represented biological
processes that responded to HNE in a quick manner, including
‘‘cytoplasmic sequestering of protein’’, ‘‘negative regulation of
transcription factor import’’, and ‘‘cellular response to stimulus’’
etc. (Table S1). Down-regulation of the biological processes
‘‘cytoplasmic sequestering of protein’’ and ‘‘negative regulation
of transcription factor import’’ at 6 h will lead to the release of
transcription factors that are sequestered in the cytosol, which is
consistent with the significant increase in overall transcription after
6 h of HNE treatment. One gene set, ‘‘pyrimidine deoxyribonu-
cleotide metabolism’’, showed a significant response for the 24 h
treatment (adjusted p-value=0) but not for 6 h treatment
(adjusted p-value=0.33). These results indicated that although
both signaling and metabolic changes were involved in oxidative
stress, metabolism response was slower than the signaling
response, e.g. transcription factor import.
Discussion
In this paper, we have proposed linear mixed models for the
analysis of microarray data at the pathway-level. This flexible,
unified and practical approach can be easily implemented in
common statistical software packages. The proposed model makes
three main improvements over popular methods for gene-set
testing: improved power through testing location shift of gene-set
genes, more refined modeling of covariance structure between
genes through specification of random effects, and the ability to
account for complicated experimental designs through inclusion of
design factors and covariate effects.
As suggested by Tian et al. [14], power is lost when GSEA tests
Q1 (genes in a gene-set show the same pattern of associations with
the phenotype compared with the rest of the genes) but generates
the null distribution of test statistic under hypothesis Q2 (all genes
in gene-set are not associated with outcome) by permuting
samples. In addition, the alternative hypothesis that is of interest
for Q1 is more likely to be location shift for genes in the gene-set
compared to background genes; the use of an omnibus test such as
the Kolmogorov test by GSEA may result in further loss in power
and produce false positives for tightly correlated gene-sets. Our
proposed method provides a simple way to test for location shifts in
Q1 while accounting for covariance structure between genes at the
same time. It provides increased power while still maintaining
control of the false positive rate.
The use of random effects to account for a general covariance
structure that varies according to genes in the proposed models
represent ourefforts for improving covariance structure modeling of
current parametric methods. False positives are likely to result when
dependency between genes are not accounted for [15], or through
Figure 2. Receiver Operating Characteristic Curves for Mixed Model, GSEA and PAGE using simulated data. tot_p=proportion of
genes with treatment effect added to treatment group in gene–set 1; up_p=among treated genes, the proportion of genes for which positive
treatment effect mu was added; 12up=among treated genes, the proportion of genes for which negative treatment effect –mu was added. See text
for details of simulation experiment.
doi:10.1371/journal.pgen.1000115.g002
Figure 3. Workflow and results for Mixed Model analysis of HNE dataset. When individual tests were conducted with 6 hr treatment
samples and 24 hr samples separately, only 5 and 1 gene-sets were significant at 0.01 FDR level. However, when all samples were used, for testing
gene-sets with non-significant Duration6Linear Trend interaction, 40 gene-sets were significant at 0.01 FDR level. This shows pooling data with
similar trends from both treatment durations improves the statistical power for identifying biologically meaningful gene sets.
doi:10.1371/journal.pgen.1000115.g003
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array [23]. Our proposed model, although may not be perfect,
provides a way to capture the primary heterogeneous covariance
structure between genes. As genes operate withcomplex covariation
patterns, covariance structure modeling is a challenge for
parametric methods and future study with further refined modeling
of dependencies between genes will extend the power and potential
of mixed models and other parametric methods.
On the other hand, the strength of parametric methods such as
the proposed mixed models lie in their ability to account for
complicated designinformation. When there are multiple sources of
covariation in the data, permutation or resampling methods are
often difficult to employ. In contrast, mixed Models 1 and 2 can be
easily extended to handle a variety of more complex designs. For
example, for two-color arrays and other arrays with multiple
measurements per gene on each array, Model 1 can be augmented
with additional random effects corresponding to spot or block
effects.Whenarraysareprocessedinmultiplebatches,abatcheffect
can be added to the model to adjust for systematic effects from
different batches. Similarly, other random effects from blocks and
sites where the experiments were performed can also be
incorporated into the models. In the A Dose Response Study
section, although we have analyzed a dose response study, time-
course experiments can also be analyzed in a similar way. For
example, for a time-course study with two treatments and four time
points, a mixed model with fixed effects Treatment, Time and
Treatment6Time plus random effects can be constructed. In
addition, these models can be further extended to accommodate
design information such as matched case-control pairs. Littell et al.
[29] provides a comprehensive set of examples covering a wide
range of mixed models and related covariance structures. Tests for
multiple interaction effects in these and numerous other mixed
model settings canprovide valuable sentinels for scientificdiscovery.
Supporting Information
Figure S1 Average standardized gene expression values for each
dose and each treatment duration.
Found at: doi:10.1371/journal.pgen.1000115.s001 (0.77 MB PDF)
Table S1 Supplementary table for HNE data.
Found at: doi:10.1371/journal.pgen.1000115.s002 (0.24 MB
XLS)
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